BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression

Poly (ADP-ribose) polymerase (PARP) inhibitors offer a significant clinical benefit for triple-negative breast cancers (TNBCs) with BRCA1/2 mutation. However, the narrow clinical indication limits the development of PARP inhibitors. Phosphoinositide 3-kinase (PI3K) inhibition sensitizes BRCA-profici...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yu, Wang, Yuantao, Zhang, Wanpeng, Wang, Xinchen, Chen, Lu, Wang, Shuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910492/
https://www.ncbi.nlm.nih.gov/pubmed/33637776
http://dx.doi.org/10.1038/s41598-021-82990-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910492/
https://www.ncbi.nlm.nih.gov/pubmed/33637776
http://dx.doi.org/10.1038/s41598-021-82990-y

Ejemplares similares